Mirum Pharmaceuticals (MIRM) Q4 2024 earnings summary

Executive summary

• Achieved 2024 net product sales of $336.4 million, up from $178.9 million in 2023, reflecting strong commercial growth across all three approved ultra-rare disease medicines and a robust pipeline with expanding patient populations.

• Global commercial reach with LIVMARLI expanded to 30 countries, including major European markets, and a pipeline targeting multi-billion dollar orphan indications in hepatology, GI, and rare genetic neurology.

• Portfolio includes LIVMARLI, CHOLBAM, and CTEXLI, with four additional indications in development and significant progress in 2024 through new approvals, label expansions, and pipeline advancements.

• Strategic priorities include global expansion of commercial medicines, advancing pipeline assets, selective product acquisitions, and maintaining financial discipline.

• 2025 net product sales guidance is $420–$435 million, with continued positive cash flow expected and a $293 million cash balance at FY2024.

Financial highlights

• 2024 net product sales reached $336.4 million, up from $178.9 million in 2023; Q4 2024 net product sales were $99.4 million, a 43% year-over-year increase.

• LIVMARLI 2024 net product sales were $213.3 million, a 50% increase over 2023; Bile acid medicines generated $123.1 million in 2024 sales.

• Total operating expenses for 2024 were $424.5 million, including R&D of $140.6 million and SG&A of $202.2 million.

• Net loss for 2024 was $87.9 million, improved from $163.4 million in 2023; operating loss was $87.6 million, improved from $109.2 million in 2023.

• Ended 2024 with $293 million in cash, cash equivalents, and investments, up from $286.3 million at year-end 2023.

Outlook and guidance

• 2025 net product sales are projected between $420 million and $435 million, with positive cash flow anticipated.

• Key milestones for 2025–2026 include completion of VISTAS (PSC) and VANTAGE (PBC) trial enrollments, and initiation of MRM-3379 Phase 2 study in Fragile X Syndrome.

• VISTAS study for volixibat in PSC to complete enrollment in H2 2025; topline data expected 2026.

• VANTAGE study in PBC and LIVMARLI EXPAND Phase 3 study expected to complete enrollment in 2026.

• Anticipate adding close to $100 million to the top line in 2025.